Mounjaro vs. Ozempic: Dual Agonist vs. Single Agonist for Type 2 Diabetes
Both are approved for type 2 diabetes and both ship as weekly pens, but tirzepatide's second receptor target is the headline difference.
By the GLP Semaglutide editorial team · Last updated July 28, 2026
Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved for type 2 diabetes management alongside diet and exercise. Mounjaro is a dual GIP/GLP-1 receptor agonist; Ozempic acts on the GLP-1 receptor alone.
Dosing structure
Both drugs use a gradual dose-escalation schedule to reduce gastrointestinal side effects, starting at a low dose and increasing every four weeks based on tolerability, up to the labeled maintenance range for each drug.
Choosing between them
Insurance formulary placement, supply availability, and a patient's individual response and side-effect tolerance typically drive the choice more than any single efficacy statistic. This is a prescribing decision, not a self-directed one.